Click here to get full coverage on VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug  Stocktwits

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits

Click here to get full coverage on Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors - PR Newswire

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors  PR Newswire

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors - PR Newswire

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates  Yahoo Finance

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis  TradingKey

Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Click here to get full coverage on Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - PR Newswire

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis  PR Newswire

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - PR Newswire

Click here to get full coverage on How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus - Yahoo Finance

How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus  Yahoo Finance

How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus - Yahoo Finance

Click here to get full coverage on VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits

VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug  Stocktwits

VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits

Click here to get full coverage on Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - PR Newswire

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists  PR Newswire

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - PR Newswire

Click here to get full coverage on Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness - Yahoo Finance

Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness  Yahoo Finance

Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness - Yahoo Finance

Click here to get full coverage on VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains?  Stocktwits

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits

Click here to get full coverage on Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods - PR Newswire

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods  PR Newswire

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods - PR Newswire

Click here to get full coverage on Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now  Yahoo Finance

Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Click here to get full coverage on Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - PR Newswire

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years  PR Newswire

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - PR Newswire

Click here to get full coverage on VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains - Yahoo Finance

VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains  Yahoo Finance

VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains - Yahoo Finance

Click here to get full coverage on Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - PR Newswire

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years  PR Newswire

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - PR Newswire

Click here to get full coverage on Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PR Newswire

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis  PR Newswire

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PR Newswire

Click here to get full coverage on Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - PR Newswire

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence  PR Newswire

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - PR Newswire

Click here to get full coverage on Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results - PR Newswire

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results  PR Newswire

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines - PR Newswire

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines  PR Newswire

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines - PR Newswire

Click here to get full coverage on Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PR Newswire

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis  PR Newswire

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PR Newswire

Click here to get full coverage on Vanda (NASDAQ: VNDA) director awarded 41,600 RSU-based shares - Stock Titan

Vanda (NASDAQ: VNDA) director awarded 41,600 RSU-based shares  Stock Titan

Vanda (NASDAQ: VNDA) director awarded 41,600 RSU-based shares - Stock Titan

Click here to get full coverage on VNDA|Vanda Pharmaceuticals Inc|Price:6.000|Chg%:0.20 - TradingKey

VNDA|Vanda Pharmaceuticals Inc|Price:6.000|Chg%:0.20  TradingKey

VNDA|Vanda Pharmaceuticals Inc|Price:6.000|Chg%:0.20 - TradingKey

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) grants director 41,600 RSUs vesting in 2027 - Stock Titan

Vanda Pharmaceuticals (VNDA) grants director 41,600 RSUs vesting in 2027  Stock Titan

Vanda Pharmaceuticals (VNDA) grants director 41,600 RSUs vesting in 2027 - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis  TradingKey

Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Click here to get full coverage on Vanda maps out 3 May investor events, including a live webcast - Stock Titan

Vanda maps out 3 May investor events, including a live webcast  Stock Titan

Vanda maps out 3 May investor events, including a live webcast - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant - Stock Titan

Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant  Stock Titan

Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award - Stock Titan

Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award  Stock Titan

Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award - Stock Titan

Click here to get full coverage on $VNDA stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$VNDA stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$VNDA stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) director granted 41,600 RSU shares vesting in 2027 - Stock Titan

Vanda Pharmaceuticals (VNDA) director granted 41,600 RSU shares vesting in 2027  Stock Titan

Vanda Pharmaceuticals (VNDA) director granted 41,600 RSU shares vesting in 2027 - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) SVP McGuire reports RSU awards vesting through 2029 - Stock Titan

Vanda Pharmaceuticals (VNDA) SVP McGuire reports RSU awards vesting through 2029  Stock Titan

Vanda Pharmaceuticals (VNDA) SVP McGuire reports RSU awards vesting through 2029 - Stock Titan

Click here to get full coverage on 80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel - Stock Titan

80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel  Stock Titan

80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel - Stock Titan

Click here to get full coverage on Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag - Yahoo Finance

Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag  Yahoo Finance

Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag - Yahoo Finance

Click here to get full coverage on $VNDA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

$VNDA stock is up 11% today. Here's what we see in our data.  Quiver Quantitative

$VNDA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" - PR Newswire

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"  PR Newswire

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" - PR Newswire

Click here to get full coverage on Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results  PR Newswire

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire

Click here to get full coverage on VNDA Stock On Track To Open At Three-Year High – FDA Clears First New Motion Sickness Drug In Decades - Stocktwits

VNDA Stock On Track To Open At Three-Year High – FDA Clears First New Motion Sickness Drug In Decades  Stocktwits

VNDA Stock On Track To Open At Three-Year High – FDA Clears First New Motion Sickness Drug In Decades - Stocktwits

Click here to get full coverage on VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects - Yahoo Finance

VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects  Yahoo Finance

VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects - Yahoo Finance

Click here to get full coverage on Vanda (NASDAQ: VNDA) investors approve directors, auditor and equity plan shares - Stock Titan

Vanda (NASDAQ: VNDA) investors approve directors, auditor and equity plan shares  Stock Titan

Vanda (NASDAQ: VNDA) investors approve directors, auditor and equity plan shares - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid - simplywall.st

Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid  simplywall.st

Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid - simplywall.st

Click here to get full coverage on Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences - PR Newswire

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences  PR Newswire

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences - PR Newswire

Click here to get full coverage on Vanda stock’s explosive rally may be more hype than substance - TradingView

Vanda stock’s explosive rally may be more hype than substance  TradingView

Vanda stock’s explosive rally may be more hype than substance - TradingView

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) grants director 57,101 time-based RSUs - Stock Titan

Vanda Pharmaceuticals (VNDA) grants director 57,101 time-based RSUs  Stock Titan

Vanda Pharmaceuticals (VNDA) grants director 57,101 time-based RSUs - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha

Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA)  Seeking Alpha

Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha

Click here to get full coverage on Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA) - Seeking Alpha

Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA)  Seeking Alpha

Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA) - Seeking Alpha

Click here to get full coverage on H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21 - Moomoo

H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21  Moomoo

H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21 - Moomoo

Click here to get full coverage on A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia - simplywall.st

A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia  simplywall.st

A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia - simplywall.st

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail

Click here to get full coverage on VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t  GuruFocus

VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Click here to get full coverage on FDA grants first drug approval hearing in 40 years over jet lag pill - Stock Titan

FDA grants first drug approval hearing in 40 years over jet lag pill  Stock Titan

FDA grants first drug approval hearing in 40 years over jet lag pill - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role - Stock Titan

Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role  Stock Titan

Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution  TradingKey

Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Click here to get full coverage on A 180-day drug review rule could stretch to 10-12 months under FDA plan - Stock Titan

A 180-day drug review rule could stretch to 10-12 months under FDA plan  Stock Titan

A 180-day drug review rule could stretch to 10-12 months under FDA plan - Stock Titan

Click here to get full coverage on CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals - timothysykes.com

CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals  timothysykes.com

CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals - timothysykes.com

Click here to get full coverage on H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛

H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21  富途牛牛

H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛

Click here to get full coverage on Vanda Pharmaceuticals (VNDA) Losses Deepen To US$239.5 Million LTM Reinforcing Bearish Narratives - simplywall.st

Vanda Pharmaceuticals (VNDA) Losses Deepen To US$239.5 Million LTM Reinforcing Bearish Narratives  simplywall.st

Vanda Pharmaceuticals (VNDA) Losses Deepen To US$239.5 Million LTM Reinforcing Bearish Narratives - simplywall.st

Click here to get full coverage on VANDA PHARMACEUTICALS Earnings Results: $VNDA Reports Quarterly Earnings - Quiver Quantitative

VANDA PHARMACEUTICALS Earnings Results: $VNDA Reports Quarterly Earnings  Quiver Quantitative

VANDA PHARMACEUTICALS Earnings Results: $VNDA Reports Quarterly Earnings - Quiver Quantitative

Click here to get full coverage on Vanda Pharmaceuticals Inc (VNDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Vanda Pharmaceuticals Inc (VNDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages  TradingKey

Vanda Pharmaceuticals Inc (VNDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Click here to get full coverage on Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline  TradingKey

Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Click here to get full coverage on Vanda Pharma to webcast Citizens Life Sciences talk from Miami on March 11 - Stock Titan

Vanda Pharma to webcast Citizens Life Sciences talk from Miami on March 11  Stock Titan

Vanda Pharma to webcast Citizens Life Sciences talk from Miami on March 11 - Stock Titan

Click here to get full coverage on Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks - StocksToTrade

Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks  StocksToTrade

Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks - StocksToTrade

Click here to get full coverage on VNDA: HC Wainwright & Co. Raises Price Target to $24.00, Maintai - GuruFocus

VNDA: HC Wainwright & Co. Raises Price Target to $24.00, Maintai  GuruFocus

VNDA: HC Wainwright & Co. Raises Price Target to $24.00, Maintai - GuruFocus

Click here to get full coverage on Vanda Pharmaceuticals Inc (VNDA) Institutional Confidence - TradingKey

Vanda Pharmaceuticals Inc (VNDA) Institutional Confidence  TradingKey

Vanda Pharmaceuticals Inc (VNDA) Institutional Confidence - TradingKey

Click here to get full coverage on Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week (NASDAQ:VNDA) - Seeking Alpha

Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week (NASDAQ:VNDA)  Seeking Alpha

Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week (NASDAQ:VNDA) - Seeking Alpha

Click here to get full coverage on Key facts: Vanda Pharmaceuticals shares up 38% on FDA approval; Bysanti to launch by Q3 2026 - TradingView

Key facts: Vanda Pharmaceuticals shares up 38% on FDA approval; Bysanti to launch by Q3 2026  TradingView

Key facts: Vanda Pharmaceuticals shares up 38% on FDA approval; Bysanti to launch by Q3 2026 - TradingView

Click here to get full coverage on Curious about the stocks that are showing activity after the closing bell on Friday? - ChartMill

Curious about the stocks that are showing activity after the closing bell on Friday?  ChartMill

Curious about the stocks that are showing activity after the closing bell on Friday? - ChartMill

Click here to get full coverage on Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com

Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks  timothysykes.com

Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com

Click here to get full coverage on VNDA Projected Revenue Forecast for 2026 at $258.2 Million - GuruFocus

VNDA Projected Revenue Forecast for 2026 at $258.2 Million  GuruFocus

VNDA

Price Chart

Key Statistics

Technicals

About VNDA

Latest News

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors - PR Newswire

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers